143-37-3

Usage

Uses

Used in Pharmaceutical Industry:
Acetamidine Base is used as a reagent for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving existing ones. Its strong basic nature facilitates reactions with a wide range of acids, making it a valuable component in the production process.
Used in Dye Industry:
In the dye industry, Acetamidine Base is utilized as a reagent in the production of dyes, enhancing the color properties and stability of the final products. Its ability to participate in various chemical reactions allows for the creation of a diverse array of dyes with different characteristics.
Used in Organic Synthesis:
Acetamidine Base is used as a catalyst in certain chemical reactions, accelerating the process and improving the yield of the desired products. Its role in organic synthesis is crucial for the production of a variety of organic compounds, including those used in various industries.
Used as an Intermediate:
Acetamidine Base serves as an intermediate in the synthesis of other organic compounds, playing a pivotal role in the creation of complex molecules and contributing to the advancement of chemical research and development.

InChI:InChI=1S/C2H6N2/c1-2(3)4/h1H3,(H3,3,4)

Upstream product

• 60-35-5 acetamide 
• 124-42-5 acetamidine hydrochloride 
• 58052-80-5 2,4,6-trimethyl-hexahydro-[1,3,5]triazine; trihydrate 
• 2678-54-8 ketene diethyl acetal 
• 98-10-2 benzenesulfonamide 
• 64-19-7 acetic acid 
• 7647-01-0 hydrogenchloride 
• 696-23-1 2-methyl-5-nitro-1H-imidazole 
• 3599-62-0 2-methyl-4,6-diphenyl-1,3,5-triazine 
• 7664-41-7 ammonia 
• 17338-96-4 8-methylxanthine 
• 75-05-8 acetonitrile 
• 2208-07-3 ethyl acetimidate hydrochloride 
• 88497-04-5 acetamidine formic acid salt 

Downstream Products

• 6622-92-0 2,6-dimethyl-1H-pyrimidin-4-one 
• 3599-87-9 2-methyl-sym-triazine 
• 1722-15-2 2,4-Dimethyl-s-triazin 
• 14278-61-6 6-amino-2,5-dimethyl-3H-pyrimidin-4-one 
• 101168-65-4 N-acetimidoyl-N'-p-tolyl-thiourea 
• 65818-01-1 2-methyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one 
• 21734-85-0 5-chloro-3-methyl-1,2,4-thiazole 
• 823-94-9 2,4,6-trimethyl-s-triazine 
• 698-29-3 2-methyl-4-amino-5-cyanopyrimidine 
• 5053-43-0 2-methylpyrimidine 
• 27058-54-4 2-methyl-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile 
• 5472-46-8 ethyl 4-amino-2-methyl pyrimidine-5-carboxylate 
• 23676-63-3 N-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-acetamide 
• 55933-85-2 acetyl-5 dimethyl-2,4 pyrimidine 

Relevant academic research and scientific papers

Development of two scalable syntheses of 4-amino-5-aminomethyl-2- methylpyrimidine: Key intermediate for vitamin b1

Two scalable processes for the synthesis of 4-amino-5-aminomethyl-2- methylpyrimidine (2) are described. In the first approach, the less expensive 2-cyanoacetamide was reacted with Vilsmeier reagent to afford enamine 18, followed by the condensation with acetamidine to produce the 4-amino-2-methylpyrimidine-5-carbonitrile (6); subsequent hydrogenation gave 2 in 65% overall yield. In the second approach, malononitrile was treated with the ionic salt 21, prepared in situ from DMF and dimethyl sulfate, to give 18, which, without isolation was reacted with acetamidine hydrochloride to afford the common intermediate 6. Overall yield of this approach was 70%. Both methods are performed in a convenient manner suitable for industrial use.

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments

GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES

Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

Process for the preparation of 2-substituted 4-amino-5-cyanopyrimidines

A compound of the formula wherein R1 is C1-4 alkyl or phenyl, is prepared by reacting a dicyanomethanide of the formula wherein M is an alkali or alkaline earth metal and r is 1 or 2, with carbon monoxide to obtain a dicyanoethenolate of the formula which is acylated to obtain an acyloxymethylenemalononitrile of the formula ???????? (NC)2=CH-OCOR2?????(IV), wherein R2 is C1-4 alkyl, which in turn is reacted with an amidine of the formula to obtain the 4-amino-5-cyanopyrimidine of the formula I. The compound of formula I, wherein R is methyl, is an intermediate in a synthesis of thiamin (vitamin B1).

2-HYDROXY-1-OXO 1,2 DIHYDRO ISOQUINOLINE CHELATING AGENTS

The invention provides a new class of strongly chelating multidentate ligands based on a 2-hydroxy-1-oxo-1,2-dihydro-isoquinoline-3-carboxylic acid scaffold (hereafter 1,2-HOIQO) in combination with polyamine backbones. The extremely stable bidentate 1,2- HOIQO moiety can be synthesized by standard synthetic methodology on a large scale. An advantageous feature is the possibility to introduce a wide range of substituents on the benzene ring by standard transformations (like electrophilic aromatic substitutions). This allows, for example, for the tuning of chemical, photophysical, and solubility properties, as well as the attachment of functional moieties, relevant for sensing and imaging applications (e.g. DNA, proteins, antibodies, fluorophores, etc.). The combination of the 1,2-HOIQO chelators with polyamine backbones provides very strongly binding ligands for a variety of metals including first-row transition metals, lanthanides, actinides, etc. Metal complexes of this kind are expected to be useful in a number of applications (e.g. luminescence, MRI, actinide sequestering, metal chelation therapy, metal radioisotope labeling, etc.).

Unusually weak binding interactions in tetrazole-amidine complexes

Tetrazoles frequently replace carboxylic acids in pharmaceutical drugs. However, while the binding modes of tetrazolate and carboxylate anions in amidinium complexes turns out to be similar, the association constant of the former is 2-3 orders of magnitude smaller in DMSO. Crystal structures revealed that the N...H-N hydrogen bonds in amidinium tetrazolates are bent (162° and 169°) and noticeably longer (N...N 2.96 A) than corresponding hydrogen bonds in both amidinium carboxylates and ammonium tetrazolates.

ANTIPARASITIC TERPENE ALKALOIDS

The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof

The present invention is to provide a compound of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic heterocyclic ring, the ring B an optionally substituted 5- to 6-membered aromatic homocyclic ring or an optionally sub

Use of optically active cyclic N,N-dialkyl aminals in asymmetric induction.

[reaction: see text]Cyclization of the optically active ketone N,N-dialkyl aminals A affords the diastereomer B as the major product with diastereoselectivities ranging from nearly 1:1 to essentially 100:0 depending on the cyclization studied.